Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder (VLZ-MD-22) (VLZ-MD-22)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02372799|
Recruitment Status : Recruiting
First Posted : February 26, 2015
Last Update Posted : February 22, 2018
|Condition or disease||Intervention/treatment||Phase|
|Major Depressive Disorder||Drug: Vilazodone Drug: Placebo Drug: Fluoxetine||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||470 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||A Multicenter, Double-blind, Placebo- and Active-Controlled Parallel-Group Evaluation of the Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder|
|Actual Study Start Date :||February 28, 2015|
|Estimated Primary Completion Date :||September 8, 2018|
|Estimated Study Completion Date :||September 8, 2018|
Vilazodone tablets, 5mg, 10mg and 20mg. Oral administration, once per day.
Other Name: Viibryd
Placebo Comparator: Placebo
Dose-matched placebo tablets or capsules, oral administration, once per day.
Active Comparator: Fluoxetine
Fluoxetine capsules, 10mg and 20 mg. Oral administration, once per day.
Other Name: Prozac
- Change in Children's Depression Rating Scale-Revised (CDRS-R) Total Score [ Time Frame: From Baseline to Week 8 ]
- Change in Clinical Global Impressions-Severity (CGI-S) Score [ Time Frame: From Baseline to Week 8 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02372799
|Contact: Clinical Trial Registries Team||866-369-5227||IR-CTRegistration@allergan.com|
Show 64 Study Locations
|Study Director:||Emily McCusker, PhD||Forest Research Institute, an affiliate of Allergan plc.|